Respicardia Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Total Funding:$98.4M
Industry:Medical Equip
Founded:2006
Lead Investor(s):ZOLL Medical Corporation
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Respicardia's estimated annual revenue is currently $14.8M per year.
  • Respicardia received $58.5M in venture funding in December 2017.
  • Respicardia's estimated revenue per employee is $242,770
  • Respicardia's total funding is $98.4M.

Employee Data

  • Respicardia has 61 Employees.
  • Respicardia grew their employee count by 42% last year.
  • Respicardia currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Devicix
N/A0N/AN/A
C-Axis and C-Ax...
$15.1M711%N/A
Gemini Medical/...
$16.6M7820%N/A
Urologix
N/A53N/AN/A
Conventus Ortho...
$11.3M479%N/A
Walman Optical
$69.8M3292%N/A
Respicardia
$14.8M6142%N/A
Osprey Medical
$16.1M6718%N/A
Patterson Denta...
$815.5M3845N/AN/A
RespirTech
$54.2M2562%N/A
Missing a competitor? Contribute!?
Submit

Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remed® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular healthone breath at a time.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

61

Number of Employees

$14.8M

Revenue (est)

1

Current Jobs

42%

Employee Growth %

$98.4M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Tim HauchChief Financial OfficerEmail Available
Todd GoblishVP Research/DevelopmentEmail Available
Michael BrownSouth West Territory ManagerEmail Available
Bill ReidyTerritory ManagerEmail Available
Jodie AlwinDirector Of Medical Education And TrainingEmail Available
Mark SartoryTerritory ManagerEmail Available
Blair EastonTerritory ManagerEmail Available
Frank PiskolichGeneral CounselEmail Available
Scott McKaneSenior Principal Statistician And Data ManagementEmail Available
Jill FrickeClinical Territory ManagerEmail Available

Respicardia News

09/03/2019 - Study: Respicardia's sleep apnea tech effective over 3 years

A new study of Respicardia's Remede central sleep apnea (CSA) implant showed long-term safety and sustained improvement in sleep metrics ...

01/14/2019 - Integer Supports Respicardia's Commercialization in the ...

“We're honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer's Cardiac ...

09/03/2019 - New med-tech investment firm Vensana Capital launches $225 million fund

At Versant, he invested in a number of Minnesota companies like Metavention, Respicardia and Monteris Medical. Vensana, however, isn't ...

Respicardia Funding

DateAmountRoundLead InvestorsReference
2014-07-14$2.0MUndisclosedArticle
2014-10-30$20.0MUndisclosedSorin GroupArticle
2017-12-19$58.5MUndisclosedZOLL Medical CorporationArticle

Respicardia Executive Hires

DateNameTitleReference
2012-11-28Jay MillerhagenVP Clinical Affairs/Market DevelopmentArticle